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Intravenous Dezocine for Postoperative Pain:
A Double-Blind, Placebo-Controlled
Comparison With Morphine
Uma A. Pandit, MD, S aria P. Kothary, MD, and Sujit K. Pandit, MD, PhD
Dezocine, a new mixed agonist-antagonist opioid analgesic, and morphine were com-
pared in a double-blind study in 206 patients with postoperative pain. The analgesic
efficacy of single intravenous injections of dezocine (2.5, 5.0, and 10.0 mg), morphine (5.0
mg), and placebo was assessed by verbal and visual scales at regular intervals for six hours
after administration. All active treatments provided greater pain relief than placebo. Pain
relief with dezocine 5 and 10 mg was significantly greater (P < .05) than with placebo for
up to four and five hours, respectively, and with morphine up to one hour. Pain relief
scores were significantly higher (P < .05) with morphine than with placebo at all
observations except that of the fifth hour, and higher with dezocine 2.5 mg than with
placebo for the first 30 minutes. Doses of 5 and 10 mg of dezocine produced approximately
the same peak analgesic effect, with the larger dose having a longer duration of effect. All
active treatments produced mild to moderate sedation. Side effects were few and mild or
moderate with all of the treatments. The physician’s and the patients’ evaluations favored
dezocine -in a dose-dependent order, with morphine 5 mg rated lower than dezocine 5 mg
and higher than dezocine 2.5 mg.
T he need for a potent analgesic with few side
effects and a low dependence liability has led to
the introduction of the mixed agonist-antagonist
opioid analgesics for clinical use. Dezocine, a synthet-
ic bridged aminotetralin (Figure 1) with structural
similarities to the benzomorphan compounds, is such
an agent. In standard animal analgesic tests, it was
seven to 18 times as potent as morphine with a
therapeutic index greater than 1,000.1.2 In tests for
dependence liability, dezocine did not substitute for
morphine or produce dependence when chronically
administered to monkeys.2 In dogs, dezocine pro-
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duced substantially less bronchoconstriction, respira-
tory depression, hypotension, and histamine release
than did morphine or pentazocine.3
In humans, dezocine 10 mg has been reported to be
equipotent to morphine 10 mg4 and meperidine 50 to
100 mt after intramuscular administration. A ceiling
effect for respiratory depression was found at a dose
of dezocine 30 mg/70 kg.6
This study was designed to compare the safety and
efficacy of single intravenous injections of dezocine
(2.5, 5, or 10 mg), morphine (5.0 mg), and placebo in
patients with moderate to severe postoperative pain.
PATIENTS AND MFHODS
A total of 206 patients with moderate or severe pain
participated in this study. The protocol and the con-
sent form were approved by the Committee to Review
Grants for Clinical Research and Investigation
Involving Human Beings at the University of Michi-
gan Medical Center. All patients gave written
informed consent. Pregnant women, patients sensitive
to opioid analgesics, and those with a history of abuse
of these agents were excluded. All patients were in
Figure 1. Chemical structure of dezocine.
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American Society of Anesthesiologists physical status
I or II and underwent general surgical, gynecologic,
or orthopedic procedures under general anesthesia.
There was no restriction in the choice of anesthetic
agents; however, patients who had received an anal-
gesic within three hours or a psychotropic drug within
six hours were excluded from the study.
When the patients complained of moderate to
severe pain in the recovery room, they were randomly
assigned to one of five treatment groups and given a
single intravenous injection of either dezocine 2.5, 5,
or 10 mg; morphine 5 mg, or placebo (normal saline) in
a double-blind fashion. Pain intensity was assessed at
baseline, and both pain intensity and pain relief were
assessed at 15, 30, and 60 minutes and then hourly for
six hours after drug administration.
Three analgesic efficacy scales were employed at
each observation time. Pain intensity was assessed
verbally and rated as none (0), mild (1), moderate (2),
or severe (3). Pain relief was rated as complete (4), alot
(3), moderate (2), little (1), none (0), or worse (-1). A
visual analogue pain intensity scale, a 100-mm line
whose terminal points represented “no pain” and
“worst pain I’ve ever felt,” also was used to evaluate
pain intensity. Patients who did not receive at least
moderate pain relief within 30 minutes were offered a
standard rescue analgesic (morphine) and were with-
drawn from the study. These patients were consid-
ered treatment failures and were assigned scores
corresponding to the baseline pain intensity and to no
relief for the observations beyond the point of reme-
dication.
Several analgesic measures were derived from the
patients’ subjective assessments. Differences from
baseline in verbal pain intensity (PID scores) and
analogue pain intensity (PAID scores) were deter-
mined at each observation time. Weighted PID and
PAID scores (i.e., each score multiplied by the propor-
tion of an hour since the last reading) were added to.
determine cumulative efficacy measures (SPID and
SPAID scores, respectively). Individual total pain
relief (TOTPAR) scores were calculated by adding
weighted pain relief scores in a similar fashion.
Vital signs (arterial blood pressure, pulse, and
respiratory rate) and degree of sedation (marked [3],
moderate [2], mild [1], and none [0] were recorded at
all observation times. Adverse effects were recorded,
and their relation to the study medication was deter-
mined. Discomfort at the site of injection was also
noted.
At the end of the study, the investigator provided an
overall clinical judgment as to whether the treatment
was satisfactory on the basis of the degree and
duration of pain relief (at least 50% pain relief for at
least 60 minutes) and the presence or absence of
adverse reactions. Each patient also gave a global
assessment (excellent [4], good [3], fair [2], and poor [1])
of his or her treatment.
Statistical Analysis
The treatment groups were compared with respect to
age, weight, and baseline pain analogue scores, using
a one-way analysis of variance, with pairwise com-
parisons made using the Newman-Keuls procedure.
Sex. race, and the baseline distributions of pain and
sedation scores were compared among the groups
using the chi-square test; Fisher’s exact test was used
for pairwise comparisons when appropriate.
Pain relief and PID scores, at each observation time
and cumulatively, were analyzed by means of the
generalized Cochran-Mantel-Haenszel procedure,
using marginal ridit scores. This approach also was
used to analyze the proportions of patients with
effective (at least moderate) pain relief, peak pain
relief scores, sedation scores, cumulative remedica-
tion rates, and overall evaluations by the patients and
physician. Comparisons of PAID and SPAID scores
among the treatment groups were made using the
analysis of covariance.
The frequencies of adverse effects were compared
among treatment groups using the chi-square test,
supplemented by Fisher’s exact test for pairwise
comparisons. Vital signs and laboratory determina-
Figure 2. Mean pain relief scores during the six-hour
evaluation period. Higher scores indicate greater pain
relief.
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tions were examined for changes within groups from
baseline using a paired t test, and comparisons among
the groups were made by analysis of covariance.
RESULTS
Patient Attributes
The overall study population consisted of 69 men
(33%) and 137 women (67%); the mean age was 36
years (range, 18 to 69 years) and the mean weight was
152 lb (range, 100 to 210 lb). Prior to receiving study
medication, 69 (33%) patients had moderate pain, and
137 (67%) patients had severe pain.
With the exception of race, there were no statisti-
cally significant differences among the five treatment
groups with respect to demographic characteristics or
initial pain intensity (both verbal and analogue).
There were significantly (P < .05) more white patients
in the 5-mg morphine (95%) and placebo (98%)
groups than in the 2.5-mg dezocine group (75%). Of
the 206 patient enrolled, eight were excluded from the
efficacy analysis because they had- received fentanyl
within three hours of dosing; all patients were includ-
ed in the safety analysis.
Efficacy Assessment
Results from the three methods of efficacy assessment
were similar. The pain relief scores, which are repre-
sentative of the scores for all three efficacy measures,
are shown in Figure 2. Higher pain relief scores were
observed in the 5- and 10-mg dezocine groups and the
morphine group than in the 2.5-mg dezocine and
placebo groups. Doses of 5 and 10 mg of dezocine
provided significantly (P < .05) greater pain relief
than placebo for up to four and five hours, respective-
ly. The 5- and 10-mg doses of dezocine also provided
significantly greater (P < .05) pain relief than 2.5 mg
of dezocine for two and three hours, respectively.
Significantly (P < .05) greater pain relief scores were
observed at 15 minutes through one hour after admin-
istration of both 5 and 10 mg of dezocine than for
morphine. Similar peak effects were seen with 5 and
10 mg of dezocine, but 10 mg of dezocine provided
longer lasting analgesia. Significantly (P < .05) higher
pain relief scores were seen in the morphine 5 mg
group than in the dezocine 2.5 mg group at two hours.
The 2.5-mg dose of dezocine provided greater
(P < .05) pain relief than placebo for the first 30
minutes.
As shown in Table I, the proportions of patients
who required remedication with standard analgesics
were significantly (P < .05) lower in the dezocine 5
and 10 mg and morphine groups than in the placebo
group at most evaluations through five hours. In
addition, the cumulative remedication rates for the
dezocine 2.5 mg group were significantly (P < .05)
higher than those in the dezocine 5 mg group at one
and two hours, the dezocine 10 mg group at one, two,
three, and five hours, and the morphine group at one
through three hours, and lower than those in the
placebo group at 15 and 30 minutes.
The maximal percentage of patients with effective
TABLE I










15mm 0* 0* 0* 0* 7%
30mm 21%* 10%* 11%* 8%* 51%
1 hr 46% 21%*t 16%*t 24%*t 61%
2hr 64% 40%*t 29%*t 39%*t 85%
3 hr 77% 62%* 50%*t 55%*t 93%
4 hr 85% 69%* 66%* 74%* 95%
5 hr 90% 79%* 71%*t 79% 95%
6 hr 90% 83% 74%* 79%* 95%
Significantly lower than placebo (P <.05); tsignificantly lower than 2.5
mg of dezocine (P <.05).
TABLE U




Dezocine 2.5 mg 1.5 60.5 3.3t
Dezocmne 5 mg 3.5ff 106.3t 6.4t1:
Dezocine 10 mg 3.6ff 138.ltt 7.3ff
Morphine 5 mg 3.Ot 109.9ff 5.5ff
Placebo 0.8 22.7 1.4
*Higher scores indicate greater pain relief; tsignificantly betfer than pla-
cebo (P <.05); tsignificantly better than 2.5mg of dezocine (P <.05).
SPID = sum of pain intensity difference scores; SPAID sum of pain an-
alogue intensity difference scores; TOTPAR = total pain relief scores.
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pain relief was highest in the dezocine 10 mg group
(82%), followed by the dezocine 5 mg group (79%), the
morphine 5 mg group (63%), the dezocine 2.5 mg
group (49%), and the placebo group (27%).
The cumulative SPID, SPAID, and TOTPAR scores
for the six-hour study period are shown in Table II.
The 10-mg dose of dezocine was the most effective,
followed by 5 mg of dezocine and 5 mg of morphine,
then 2.5 mg of dezocine, and placebo. Both the 5- and
10-mg doses of dezocine showed a significant (P < .05)
advantage over 2.5 mg of dezocine and placebo as
measured by SPID and TOTPAR scores. Morphine
showed a significant (P < .05) advantage over 2.5 mg
of dezocine and placebo as measured by SPAID and
TOTPAR scores.
Sedation
The distribution of sedation at baseline differed sig-
nificantly (P < .05) among the groups, with moderate
sedation being more frequent in the dezocine 2.5 mg
group (28%) than in the dezocine 10 mg, morphine 5
mg, and placebo groups (3%, 3%, and 5%, respective-
ly). Significantly (P < .05) more sedation was noted in
each of the four active therapy gorups than in the
placebo group at two or more time periods through
two hours, with the highest mean sedation scores
generally occurring in the dezocine 10 mg group. For
all groups, however, the peak mean scores during
therapy ranged between “mild” and “moderate.”
Vital Signs
With the exception of one patient in dezocine 10-mg
group who became hypotensive (see below), clinically
significant changes in vital signs were not apparent.
Adverse Effects
The most commonly reported adverse effects related
to the study medications were nausea and vomiting;
one or both of these effects occurred in two of 40
patients (5%) in the dezocine 2.5 mg group, two of 42
(5%) in the dezocine 5-mg group, one of 41 (2%) in the
dezocine 10-mg group, one of 41 (2%) in the morphine
group, and two of 42 (5%) in the placebo group. One
additional patient became hypotensive (blood pres-
sure fell from 108/60 to 80/50 mm Hg) after receiving
dezocine 10 mg and was treated successfully with
intravenous bolus injections of fluid. Another patient
developed a skin rash after receiving morphine 5 mg.
Three patients had discomfort at the injection site
(one patient in the dezocine 5 mg group and two
patients in the morphine 5 mg group). No one was
withdrawn from the study because of adverse effects.
There were no statistically significant differences in
the incidence of adverse effects among the groups.
Overall Evaluation
The physician’s and patients’ overall evaluations are
presented in Table III. The physician’s evaluations
favored dezocine in a dose-dependent order, with
morphine 5 mg rated between 2.5 and 5 mg of
dezocine. Both the 5- and 10-mg doses of dezocin#{232}
showed a significant (P < .05) advantage over 2.5 mg
of dezocine, 5 mg of morphine, and placebo. The
patient evaluations of treatment showed a similar
order of preference, although the differences
between 5 mg of dezocine and 5 mg of morphine were
not statistically significant. Morphine showed a signif-
icant (P < .05) advantage over placebo for both evalu-
ations.
DISCUSSION
Acute or chronic pain is often inadequately treated
because of unrealistic fear of the respiratory depres-
sion and dependence liability of opioid analgesics,
which include morphine and meperidine.#{176}’9 Physi-
cians and nurses have been blamed by the medical
and lay press for treating pain inadequately.’#{176} In
response to these reports, research efforts have been
aimed toward alternative methods of administering
DEZOCINE FOR POSTOPERATIVE PAIN
CLINICAL RESEARCH: ANALGESIC DRUGS 279
TABLE lii























































opioid analgesics (e.g., patient-controlled analgesia)
and toward the use of newer agents that have fewer
side effects than those currently in use (e.g., mixed
agonist-antagonist analgesics). Agonist-antagonist an-
algesics have a ceiling effect for respiratory depres-
sion and a low abuse potential. However, some of
these agents (e.g., pentazocine) cause psychotomimet-
ic effects, presumably because they bind to sigma-
opiate receptors in the central nervous system. Dezo-
cine, a synthetic mixed agonist-antagonist opioid
analgesic, has been characterized as a partial mu
agonist with some delta-receptor activity but is virtu-
ally devoid of kappa- or sigma-receptor activity (per-
sonal communication, S. H. Snyder, Department of
Neuroscience, Pharmacology and Experimental
Therapeutics, Johns Hopkins University School of
Medicine, 1984). With such an opiate-receptor bind-
ing profile, dezocine may have less propensity to
produce psychotomimetic effects than other agonist-
antagonist agents.
In the present study, all the active treatment groups
produced more effective pain relief than did placebo.
Moreover, remedication rates after drug administra-
tion were consistently lower among patients who
received active treatment than among those who
received a placebo. Dezocine produced greater pain
relief than did similar doses of morphine (rated
satisfactory by the physician in 76% vs 53% of the
patients) with a quicker onset of action. These proper-
ties could be very useful in clinical practice whether
dezocine is used in either incremental intravenous
injections (i.e., patient-controlled analgesia) or contin-
uous intravenous infusion for postoperative pain.
Both 5- and 10-mg doses of dezocine were more
effective than 5 mg of morphine; however, whether 5-
and 10-mg doses of dezocine would also be more
effective than larger doses of morphine is impossible
to ascertain, as only one dose of morphine was used
for comparison. Because this was a double-blind
study, we were reluctant to administer larger doses of
morphine intravenously.
Some patients, who were excluded from the effica-
cy analysis, received fentanyl or morphine within
three hours of receiving dezocine and experienced
good analgesia, which suggests that the antagonist
properties of dezocine were not prominent in these
patients. Further studies are required to evaluate the
interaction of dezocine with opiates and other psycho-
tropic drugs used during anesthesia.
Thus, the results of this study indicate that dezocine
is a safe and promising analgesic that is significantly
more effective than placebo and perhaps more potent
than equal doses of morphine for the relief of acute
postoperative pain. Its rapid onset of analgesia after
intravenous administration may offer an additional
advantage.
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